@article{015a17a98a99425aaa79f74cccb9ebe9,
title = "Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs",
keywords = "cardiovascular disease, cholesterol, lipids",
author = "Virani, {Salim S.} and Akeroyd, {Julia M.} and Vijay Nambi and Heidenreich, {Paul A.} and Morris, {Pamela B.} and Khurram Nasir and Michos, {Erin D.} and Bittner, {Vera A.} and Petersen, {Laura A.} and Ballantyne, {Christie M.}",
year = "2017",
month = jun,
day = "20",
doi = "10.1161/CIRCULATIONAHA.117.028503",
language = "English (US)",
volume = "135",
pages = "2572--2574",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "25",
}